Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

NCT07072585 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT07072585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07072585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)
Lead sponsor
Children's Oncology Group
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
August 28, 2026
Completion date
September 1, 2035
Enrollment
1,708 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

stage ii t lymphoblastic leukemia/lymphoma, stage iii t lymphoblastic leukemia/lymphoma, stage iv t lymphoblastic leukemia/lymphoma, t acute lymphoblastic leukemia, t lymphoblastic lymphoma